Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis

Figures & data

Figure 1. Flow chart of the search and selection of studies.

Table 1. Baseline characteristics of the patients in four RCTs

Study (year)	Patients	Age	Sex (F:M)	Design	Trial length	ITT	Gov.ID/ Status
Pozniak et al. (2010)^Citation13	368	Case:35	Case:187:92	Randomized, blind, dummy	Week 48	Yes	NCT00110305
		Control:35	Control:60:29		Week 96		Phase III
Cohen et al. (2011)^Citation14	678	Case:36	Case:90:250	Randomized, blind, dummy		Yes	NCT00543725
		Control:36	Control:94:244		Week 48		Phase III
Molina et al. (2011)^Citation15	690	Case:36	Case:78:268	Randomized, blind, dummy		Yes	NCT00540449
		Control:36	Control:69:275		Week 48		Phase III
Cohen et al. (2012)^Citation19	786	Case: 37	Case:28:366	Randomized, blind, dummy	Week 48	Yes	STaR Study
		Control: 35	Control:27:365

Figure 2. Relative risk of viral load in patients exposed to RPV (left) versus EFV (right) at week 48.

Figure 3. Relative risk of virological failure in patients exposed to RPV (left) versus EFV (right) at week 48.

Figure 4. Relative risk of rash events in patients exposed to RPV (left) versus EFV (right) at week 48.

Figure 5. Relative risk of neurological events in patients exposed to RPV (left) versus EFV (right) at week 48.

Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24(1):55–65.

 PubMed Web of Science ®Google Scholar

Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229–237.

 PubMed Web of Science ®Google Scholar

Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–246.

 PubMed Web of Science ®Google Scholar

Cohen C, Wohl D, Arribas J, et al. STAR study: single-tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults. Paper presented at: 11th International Congress on Drug Therapy in HIV Infection; November 11–15, 2012; Glasgow, Scotland..

 Google Scholar